Gilead Sciences (GILD) Misses Q3 EPS by 8c, Revises 2014 Guidance
Gilead Sciences (NASDAQ: GILD) reported Q3 EPS of $1.84, $0.08 worse than the analyst estimate of $1.92. Revenue for the quarter came in at $6.04 billion versus the consensus estimate of $5.99 billion.
Revised 2014 Full Year Guidance
Gilead updated its full year 2014 guidance, which it initially provided on February 4, 2014, updated on July 23, 2014, and further revised on October 28, 2014:
| (In millions, except percentages and per share amounts) | Initially ProvidedFebruary 4, 2014;Reiterated April 22,2014 | UpdatedJuly 23, 2014 | Provided onOctober 28, 2014 | |||
| Net Product Sales | $11,300 - $11,500 | $21,000 - $23,000 | $22,000 - $23,000 | |||
| Non-GAAP* | ||||||
| Product Gross Margin | 75% - 77% | 85% - 88% | 86% - 88% | |||
| R&D | $2,200 - $2,300 | $2,300 - $2,400 | $2,300 - $2,400 | |||
| SG&A | $2,100 - $2,200 | $2,300 - $2,400 | $2,700 - $2,800 ** | |||
| Effective Tax Rate | 28% - 29% | 17.5% - 20.5% | 17.5% - 19.5% | |||
| Diluted EPS Impact of Acquisition-Related, Restructuring and Stock-Based Compensation Expenses | $0.63 - $0.66 | $0.63 - $0.66 | $0.63 - $0.66 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.